Tiomolibdic acid

Tiomolibdic acid
Clinical data
Trade names	Decuprate
Other names	Tetrathiomolybdic acid; choline salt: ATN-224, WTX101, ALXN1840
ATC code	A16AX22 (WHO) ;
Identifiers
CAS Number	13818-85-4; anion: 16330-92-0;
PubChem CID	4660425;
DrugBank	anion: DB05088;
ChemSpider	21494208; anion: 10619308;
UNII	206J6X63BE; anion: 91U3TGV99T;
KEGG	D12485;
CompTox Dashboard (EPA)	DTXSID60160518 ;
Chemical and physical data
Formula	H2MoS4
Molar mass	226.21 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES S=[Mo](=S)(S)S;
	InChI InChI=1S/Mo.2H2S.2S/h;2*1H2;;/q+2;;;;/p-2; Key:IEGNLZVDENYZEJ-UHFFFAOYSA-L;

Tiomolibdic acid (trade name Decuprate) is a chelating agent under investigation for the treatment of cancer and of Wilson's disease, a rare and potentially fatal disease in which the body cannot regulate copper. It is developed by Wilson Therapeutics and used in form of the salt bis-choline tetrathiomolybdate.

Wilson's disease is an autosomal recessive genetic disorder that is manifested by serious hepatic, neurologic or psychiatric symptoms. The disease is fatal if left untreated. It is estimated that 1 individual in every 30,000 to 100,000 worldwide has Wilson's disease.

Bis-choline tetrathiomolybdate has been evaluated in clinical trials in patients with various forms of cancer and has received orphan designation in the US and EU as a potential therapy against Wilson's disease.